Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations
Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations
Not yet recruiting · NCT07670156 · Registry updated 2026-09-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations | immune system disorder, inborn error of immunity | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-08 | NCT07670156 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AbbVie | 340 |
| Lisa Satter | 1 |
| National Center for Advancing Translational Sciences (NCATS) | 127 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Baylor College of Medicine | Houston | United States | 306 |
| Columbia University | New York | United States | 154 |
| Washington University in St.Louis | St Louis | United States | 2 |